Myriad Genetics Executive and Leadership Team

Benjamin Wheeler, the Chief Financial Officer at Myriad Genetics, directs all fiscal planning and capital allocation strategies. Overseeing the financial health of this molecular diagnostic firm, the Chief Financial Officer manages investor relations and long-term budgetary frameworks. Benjamin Wheeler ensures the alignment of capital expenditures with the core mission of delivering advanced testing across major diseases. By optimizing revenue cycles and cost structures, the Chief Financial Officer supports the expansion of diagnostic capabilities throughout North American markets. This leadership role involves rigorous oversight of financial reporting and risk management protocols to maintain corporate stability. Through precise fiscal analysis, the Chief Financial Officer drives sustainable growth and operational efficiency. Wheeler maintains constant communication with the Board regarding financial performance metrics. Ultimately, the Chief Financial Officer secures the necessary resources to fuel ongoing research and development initiatives, ensuring the company remains a leader in the molecular diagnostic industry.

Mark Verratti, the President at Myriad Genetics, directs the overarching operational strategy and execution of diagnostic service delivery. Overseeing the integration of research and commercial functions, the President ensures the company meets the evolving needs of the molecular diagnostic market. Mark Verratti manages the alignment of internal departments to accelerate the discovery and delivery of tests for major diseases. By optimizing operational workflows, the President drives efficiency across the entire diagnostic pipeline. This leadership role involves setting strategic priorities that enhance the company's market position and clinical impact. Verratti coordinates with the executive team to translate scientific advancements into scalable business solutions. Through rigorous performance monitoring, the President ensures the organization achieves its growth targets while maintaining high standards of diagnostic accuracy. Ultimately, Verratti guides the company toward long-term success by fostering a culture of excellence and innovation in the molecular diagnostic field.

Melissa Gonzales, the President, Women's Health, Myriad Genetics at Myriad Genetics, directs the strategic expansion and commercialization of diagnostic tests specifically tailored for women's health. Overseeing the development of specialized molecular diagnostic solutions, the President, Women's Health, Myriad Genetics ensures the delivery of high-quality clinical insights. Melissa Gonzales manages the growth of this critical business unit by identifying emerging needs in reproductive and hereditary health. By leading cross-functional teams, the President, Women's Health, Myriad Genetics drives the adoption of diagnostic tools that improve patient outcomes. This leadership role involves navigating complex clinical landscapes to ensure the accessibility of testing services. Gonzales collaborates with research and development teams to prioritize innovations that address specific health challenges. Through targeted market strategies, the President, Women's Health, Myriad Genetics expands the company's footprint in the women's health sector. Ultimately, Gonzales secures the company's position as a trusted provider of essential diagnostic information for patients and clinicians.

Amy Sarola, the Legal & Compliance Operations Chief of Staff at Myriad Genetics, architects the regulatory frameworks governing molecular diagnostic testing. Overseeing internal governance and risk mitigation, the Legal & Compliance Operations Chief of Staff ensures adherence to complex healthcare laws. Amy Sarola coordinates cross-functional efforts to maintain ethical standards across all diagnostic service lines. By streamlining compliance workflows, the Legal & Compliance Operations Chief of Staff protects the integrity of the company's research and delivery processes. This leadership role involves managing legal documentation and policy implementation to support the broader corporate strategy. Sarola facilitates communication between legal teams and executive leadership to address emerging regulatory challenges in the diagnostic sector. Through proactive monitoring of industry standards, the Legal & Compliance Operations Chief of Staff mitigates operational risks. Ultimately, Sarola safeguards the reputation of the firm while enabling the seamless execution of diagnostic testing services across diverse clinical environments.

Shereen Solaiman, the Chief People Officer at Myriad Genetics, directs talent acquisition and organizational development strategies. Overseeing the human capital requirements of this molecular diagnostic company, the Chief People Officer fosters a culture of innovation and scientific excellence. Shereen Solaiman designs comprehensive programs for employee engagement, performance management, and leadership training. By aligning workforce capabilities with the company's diagnostic mission, the Chief People Officer ensures the organization attracts top-tier scientific talent. This leadership role involves managing compensation structures and diversity initiatives to support a high-performing environment. Solaiman collaborates with other C-suite leaders to integrate human resources strategy into the broader business objectives. Through the implementation of scalable talent systems, the Chief People Officer drives organizational agility. Ultimately, Solaiman cultivates a workforce dedicated to delivering life-changing diagnostic tests, ensuring the company maintains a competitive edge in the rapidly evolving healthcare landscape.